Polymporphism of monocyte chemoattractant protein 1 (MCP1 –2518 A/G) and responsiveness to hepatitis B vaccination in hemodialysis patients

INTRODUCTION Monocyte chemoattractant protein 1 (MCP‑1) is involved in the pathogenesis of renal diseases, diabetes, and hepatitis B virus (HBV) clearance. 
OBJECTIVES The aim of the study was to evaluate the distribution of MCP1–2518 A/G (rs1024611) polymorphic variants in patients on hemodialysis (HD) with respect to their responsiveness to hepatitis B vaccination.
PATIENTS AND METHODS Patients on HD, never infected with HBV, were enrolled into the study after receiving an appropriate hepatitis B vaccine. The HD group consisted of 601 individuals who responded to vaccination with anti‑HBs titer exceeding 10 IU/l considered as protective and 153 nonresponders, in whom no adequate response was observed (anti‑HBs, ≤10 IU/l). There were 175 diabetic patients among responders and 47 diabetic patients among nonresponders. Healthy subjects served as controls (n = 437). MCP1 genotyping was determined by polymerase chain reaction–restriction fragment length polymorphism.
RESULTS The distribution of MCP1 rs1024611 polymorphic variants in controls was as follows: AA, 51%; AG, 41%; GG, 8%. There were no significant differences (P >0.05) in MCP1 distribution between the study groups and controls, independently of the occurrence of diabetes and responsiveness to hepatitis B vaccination. HD groups that were identified based on diabetic status and responsiveness to hepatitis B vaccination did not differ in MCP1 distribution.
CONCLUSIONS MCP1‑2518 A/G polymorphism is not associated with responsiveness to hepatitis B vaccination in patients on HD, independently of whether they have diabetes or not.